CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway

Published:2022-01 Issue: Volume:351 Page:109747
ISSN:0009-2797
Container-title:Chemico-Biological Interactions
language:en
Short-container-title:Chemico-Biological Interactions

Author:

Jiang ShiLong,Jiang Ting,Huang HanXue,Chen XiSha,Li LanYa,Wang ZhiBin,Fei JiangFeng,Liu Chong,Liu ZhaoQian,Cheng Yan

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference40 articles.

1. Unusual clinical presentations of malignant melanoma: a review of clinical and histologic features with special emphasis on dermatoscopic findings;Cabrera;Am. J. Clin. Dermatol.,2018

2. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma;Carlino;Crit. Rev. Oncol. Hematol.,2015

3. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy;Talebi;Nat. Commun.,2018

4. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact;Rizos;Clin. Cancer Res.,2014

5. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;Larkin;N. Engl. J. Med.,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Apoptosis-Related Specific Risk Model for Breast Cancer: From Genomic Analysis to Precision Medicine;Frontiers in Bioscience-Landmark;2024-06-27

2. Knockdown of LRP5 Promotes Proliferation and Invasion of Tongue Squamous Cell Carcinoma through Compensatory Activation of Akt Signaling;Journal of Cancer;2024

3. 2,4-Diaryl-pyrimido[1,2-a]benzimidazole derivatives as novel anticancer agents endowed with potent anti-leukemia activity: Synthesis, biological evaluation and kinase profiling;European Journal of Medicinal Chemistry;2023-10

4. Receptor tyrosine kinase inhibitors in cancer;Cellular and Molecular Life Sciences;2023-03-22

5. Receptor Tyrosine Kinase Inhibitors in Cancer Immunotherapy;2022-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3